Fierce Healthcare

Eli Lilly launches oral GLP-1 drug across US through Lilly Direct, telehealth providers

Eli Lilly has rolled out Foundayo, its oral GLP-1 pill, directly to consumers through its LillyDirect cash-pay channel, as well as to telehealth providers and pharmacies across the U.S.   | Beginning April 9,
BioPharma Dive

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.
BioSpace

With oral obesity race underway, all eyes are on Lilly’s Foundayo launch

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has come from behind the Danish rival in the weight loss space before, last time it clearly had the better drug.

Eli Lilly Expands Foundayo Access With Retail And Telehealth Partners

Eli Lilly’s oral obesity pill Foundayo, approved by the FDA in early April 2026, is now rolling out broadly across the U.S. The drug is available through Amazon Pharmacy, GoodRx, Weight Watchers programs,